Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
- 1 September 1993
- journal article
- correction
- Published by Wolters Kluwer Health in Circulation
- Vol. 88 (3), 1361-1374
- https://doi.org/10.1161/01.cir.88.3.1361
Abstract
Thrombolytic therapy significantly improves the natural history of acute myocardial infarction, but recent data suggest that current reperfusion strategies have yet to realize the maximum potential for reduction of mortality and salvage of ventricular function. Coronary patency rates as high as 85% assessed by angiography 90 minutes after initiation of treatment greatly overestimate the efficacy of thrombolytic regimens, as this conventional angiographic "snapshot" view does not satisfactorily reflect the dynamic processes of coronary artery recanalization and reocclusion or the adequacy of myocardial perfusion. In fact, only the unusual patient appears to achieve optimal reperfusion for acute myocardial infarction, with a substantial deterioration of benefit in many patients due to insufficiently early or rapid recanalization, incomplete patency with TIMI grade 2 flow or critical residual coronary stenoses, absence of myocardial tissue reflow despite epicardial artery patency, intermittent coronary patency, subsequent reocclusion, or reperfusion injury. Recently developed techniques to critically assess the quality of reperfusion, coupled with the introduction of novel pharmacological agents and an improved understanding of the roles and mechanisms of existing thrombolytic and adjunctive drugs, have provided the opportunity to overcome many of the present limitations of reperfusion therapy. Emerging strategies to achieve optimal reperfusion are directed at enhancement of the velocity and quality of thrombolysis, amelioration of the adverse effects of reperfusion, and use of alternative pathways to myocardial salvage.Keywords
This publication has 66 references indexed in Scilit:
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1989
- A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary AngioplastyNew England Journal of Medicine, 1987
- Intermittent Coronary Occlusion in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- Prevention of Myocardial Damage in Acute Myocardial Ischemia by Early Treatment with Intravenous StreptokinaseNew England Journal of Medicine, 1985
- The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Prevention of Myocardial Infarction by Very Early Treatment with Intracoronary StreptokinaseNew England Journal of Medicine, 1984